🔗 Permalink

Inventor profile of:

Patrick Joseph Roberts

City:

Durham, North Carolina

Country:

United States

Published Applications:

Last publication date:

2026-02-12

Top Assignees for applications by Patrick Joseph Roberts

The entities that hold a legal rights for patent applications filed by inventor Roberts Patrick Joseph:

G1 THERAPEUTICS, INC. 35 Research Triangle Park, NC United States
G1 Therapeutics, Inc. 5 Chapel Hill, NC United States
GI Therapeutics, Inc. 3 Research Triangle Park, NC United States
Pharmacosmos Holding A/S 2 Holbæk, Denmark
G1 Therapeutics, Inc. 1 Research Park Triangle, NC United States
PRESIDENTS AND FELLOWS OF HARVARD COLLEGE 1 Cambridge, MA United States
G1 Therapeutics 1 Chapel Hill, NC United States
G1 Therapeutics, Inc. 1 Research Traiangle Park, NC United States
INCYCLIX BIO, LLC 1 Research Triangle Park, NC United States
Brigham and Women's Hospital 1 Boston, MA United States
The University of North Carolina at Chapel Hill 1 Chapel Hill, NC United States

Recent patent applications by Roberts Patrick Joseph

Patrick Joseph Roberts from Durham, US has applied for patents for these inventions. The list has both pending applications and granted patents:

#1 | 2026-02-12

US20260041640A1

Human necessities

ADVANTAGEOUS HUMAN DOSAGE REGIMENS FOR ADMINISTRATION OF INX-315

#2 | 2023-11-30

US20230381189A1

Human necessities

TRANSIENT PROTECTION OF NORMAL CELLS DURING CHEMOTHERAPY

#3 | 2023-11-16

US20230364098A1

Human necessities

HSPC-SPARING TREATMENTS FOR RB-POSITIVE ABNORMAL CELLULAR PROLIFERATION

#4 | 2023-09-28

US20230302001A1

Human necessities

PRESERVATION OF IMMUNE RESPONSE DURING CHEMOTHERAPY REGIMENS

#5 | 2023-08-10

US20230248733A1

Human necessities

HIGHLY ACTIVE ANTI-NEOPLASTIC AND ANTI-PROLIFERATIVE AGENTS

#6 | 2023-08-03

US20230241059A1

Human necessities

ANTI-NEOPLASTIC COMBINATIONS AND DOSING REGIMENS USING CDK4/6 INHIBITOR COMPOUNDS TO TREAT RB-POSITIVE TUMORS

#7 | 2022-06-09

US20220175787A1

Human necessities

PATIENT SELECTION FOR ENHANCEMENT OF ANTI-TUMOR IMMUNITY IN CANCER PATIENTS

#8 | 2022-06-09

US20220175780A1

Human necessities

Treatment of Rb-negative tumors using topoisomerase inhibitors in combination with cyclin dependent kinase 4/6 inhibitors

#9 | 2021-09-30

US20210299130A1

Human necessities

Transient protection of normal cells during chemotherapy

#10 | 2021-09-02

US20210267986A1

Human necessities

THERAPEUTIC REGIMENS FOR TREATMENT OF CANCER USING ERIBULIN AND SELECTIVE CDK4/6 INHIBITOR COMBINATIONS

#11 | 2021-07-15

US20210213022A1

Human necessities

HSPC-sparing treatments for RB-positive abnormal cellular proliferation

#12 | 2021-03-18

US20210077498A1

Human necessities

TRANSIENT PROTECTION OF HEMATOPOIETIC STEM AND PROGENITOR CELLS AGAINST IONIZING RADIATION

#13 | 2021-02-04

US20210030758A1

Human necessities

TREATMENT OF CANCERS HAVING DRIVING ONCOGENIC MUTATIONS

#14 | 2020-11-05

US20200345743A1

Human necessities

HIGHLY ACTIVE ANTI-NEOPLASTIC AND ANTI-PROLIFERATIVE AGENTS

#15 | 2020-11-05

US20200345742A1

Human necessities

Transient protection of normal cells during chemotherapy

#16 | 2020-01-23

US20200022983A1

Human necessities

Treatment of Rb-negative tumors using topoisomerase inhibitors in combination with cyclin dependent kinase 4/6 inhibitors

#17 | 2019-10-24

US20190321370A1

Human necessities

Preservation of immune response during chemotherapy regimens

#18 | 2019-06-06

US20190167691A1

Human necessities

TRANSIENT PROTECTION OF HEMATOPOIETIC STEM AND PROGENITOR CELLS AGAINST IONIZING RADIATION

#19 | 2019-05-23

US20190151311A1

Human necessities

Anti-neoplastic combinations and dosing regimens using CDK4/6 inhibitor compounds to treat Rb-positive tumors

#20 | 2019-05-02

US20190125752A1

Human necessities

Highly active anti-neoplastic and anti-proliferative agents

#21 | 2019-03-07

US20190070185A1

Human necessities

HSPC-sparing treatments for RB-positive abnormal cellular proliferation

#22 | 2019-01-31

US20190030034A1

Human necessities

Treatment of Rb-negative tumors using topoisomerase with cyclin dependent kinase 4/6 inhibitors

#23 | 2018-12-20

US20180360841A1

Human necessities

HSPC-sparing treatments for Rb-positive abnormal cellular proliferation

#24 | 2018-12-20

US20180360840A1

Human necessities

Transient protection of normal cells during chemotherapy

#25 | 2018-08-09

US20180221378A1

Human necessities

Transient protection of normal cells during chemotherapy

#26 | 2018-01-18

US20180015096A1

Human necessities

HIGHLY ACTIVE ANTI-NEOPLASTIC AND ANTI-PROLIFERATIVE AGENTS

#27 | 2017-11-23

US20170333440A1

Human necessities

Tricyclic lactams for use in HSPC-sparing treatments for Rb-positive abnormal cellular proliferation

#28 | 2017-08-31

US20170246171A1

Human necessities

Treatment Of RB-Negative Tumors Using Topoisomerase Inhibitors In Combination With Cyclin Dependent Kinase 4/6 Inhibitors

#29 | 2017-06-29

US20170182043A1

Human necessities

Anti-neoplastic combinations and dosing regimens using CDK4/6 inhibitor compounds to treat RB-positive tumors

#30 | 2017-04-13

US20170100405A1

Human necessities

HSPC-sparing treatments for RB-positive abnormal cellular proliferation

#31 | 2017-03-09

US20170065597A1

Human necessities

Transient protection of normal cells during chemotherapy

#32 | 2017-02-09

US20170037051A1

Chemistry; metallurgy

Transient protection of normal cells during chemotherapy

#33 | 2016-10-27

US20160310499A1

Human necessities

Highly Active Anti-Neoplastic and Anti-Proliferative Agents

#34 | 2016-08-04

US20160220569A1

Human necessities

CDK4/6 Inhibitor Dosage Formulations For The Protection Of Hematopoietic Stem And Progenitor Cells During Chemotherapy

#35 | 2015-10-22

US20150299212A1

Chemistry; metallurgy

Tricyclic lactams for use in HSPC-sparing treatments for RB-positive abnormal cellular proliferation

#36 | 2015-10-22

US20150297608A1

Human necessities

Tricyclic Lactams for Use as Anti-Neoplastic and Anti-Proliferative Agents

#37 | 2015-10-22

US20150297607A1

Human necessities

Tricyclic Lactams for Use in the Protection of Normal Cells During Chemotherapy

#38 | 2015-10-22

US20150297606A1

Human necessities

Tricyclic Lactams for Use in the Protection of Hematopoietic Stem and Progenitor Cells Against Ionizing Radiation

#39 | 2015-04-23

US20150111896A1

Human necessities

HEMATOPOIETIC PROTECTION AGAINST CHEMOTHERAPEUTIC COMPOUNDS USING SELECTIVE CYCLIN-DEPENDENT KINASE 4/6 INHIBITORS

#40 | 2014-09-18

US20140275067A1

Chemistry; metallurgy

Transient protection of normal cells during chemotherapy

#41 | 2014-09-18

US20140275066A1

Human necessities

Transient protection of normal cells during chemotherapy

#42 | 2014-09-18

US20140274896A1

Human necessities

Transient Protection of Hematopoietic Stem and Progenitor Cells Against Ionizing Radiation

#43 | 2014-09-18

US20140271466A1

Chemistry; metallurgy

HSPC-sparing treatments for RB-positive abnormal cellular proliferation

#44 | 2014-09-18

US20140271460A1

Chemistry; metallurgy

Highly Active Anti-Neoplastic and Anti-Proliferative Agents

#45 | 2013-11-14

US20130303543A1

Human necessities

Protection of renal tissues from ischemia through inhibition of the proliferative kinases CDK4 and CDK6

InventorID:

530192 ⎘